TQB2618 Injection Combined Therapy

TQB2618 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB2618 Injection Combined Therapy, covering 2025-07-16 to 2025-07-16. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 1, Phase 2]

See pricing